NCT06834204 2026-03-23ACCESS-PCRutgers, The State University of New JerseyPhase NA Not yet recruiting266 enrolled
NCT07218003 2026-03-23A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Rondo TherapeuticsPhase 1 Enrolling by invitation149 enrolled
NCT04300556 2026-03-13A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesEisai Inc.Phase 1/2 Recruiting182 enrolled
NCT05922930 2026-02-19Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerM.D. Anderson Cancer CenterPhase 1/2 Recruiting51 enrolled
NCT07368985 2026-01-27Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerErasmus Medical CenterPhase 2 Not yet recruiting87 enrolled